Skip to main content
All lobbying filings

FEROX STRATEGIES

Lobbying for FRESENIUS KABI USA LLC · Generic and biosimilar pharmaceutical manufacturer

 Filing 4th Quarter - Report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Income
$50,000.00
What the client paid this registrant for the period.
Client based in
Illinois

Official filing document

 Government bodies contacted 6
  • Commerce, Dept of (DOC)
  • Executive Office of the President (EOP)
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • SENATE
  • U.S. Trade Representative (USTR)

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Lobbying activity 3
Trade (domestic/foreign)

General issues related to trade.

Health Issues

General healthcare issues related to biosimilar industries.

Pharmacy

General patent issues related to biosimilar industries.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem